(CercleFinance.com) – Jefferies is initiating a follow-up on Regeneron with an ‘underperforming’ opinion and a price target of $536, considering that the competitive environment will make it difficult for the biotech group to outperform in the future.
If he recognizes that ‘Regeneron has been one of the best names to hold in biotechnology for the past 20 years’, the broker points to intellectual property and competitive problems on Eylea which could weigh on its figures from 2024 and beyond. of the.
Jefferies also mentions an ‘unclear’ opportunity for Dupixent in COPD (chronic obstructive pulmonary disease) and a ‘historically superb pipeline that looks mixed at the moment’.
Copyright © 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
